SEC 13F Intelligence

Lion Point Capital, LP / MLTX

Lion Point Capital, LP’s Moonlake Immunotherapeutics Position

Does Lion Point Capital, LP own Moonlake Immunotherapeutics (MLTX)? Yes — 67.5K shares worth $1M (+7.52% of its 13F portfolio) as of Q1 2026.

Position Value
$1M
Q1 2026
Shares
67.5K
% of Portfolio
+7.52%
Quarters Held
3
currently held

Position History MLTX

Reported value by quarter
Q3 ’25: $483,975Q3 ’25Q4 ’25: $889,650Q4 ’25Q1 ’26: $1MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 202667.5K$1M+7.52%
Q4 202567.5K$889,650+4.60%
Q3 202567.5K$483,975+2.75%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Lion Point Capital, LP’s full portfolio or all institutional holders of MLTX.